A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Inclusion criteria: * Age ≥18 years. * Written informed consent prior to any study-related procedure * Willing and able to comply with protocol-specified procedures and scheduled evaluations * Pathological diagnosis of nasopharyngeal carcinoma (NPC) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2 * Absolute neutrophil count (ANC) \> 0.5 x 109/L * Haemoglobin \> 80 g/L * Platelet count ≥ 50 x 109/L * Total bilirubin ≤ 2 x the upper limit of normal (ULN) * Alanine transaminase (ALT) ≤ 5 x ULN * Serum creatinine ≤ 2 x ULN Exclusion criteria: * History or clinical evidence of neoplastic central nervous system (CNS) involvement. Note: Irradiated brain metastases that have been stable for \> 1 month and do not require systemic glucocorticoid administration are allowed * Major surgery within 4 weeks of ARGX-110 first dose administration * Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local radiation therapy). * Active, untreated viral, bacterial, or systemic fungal infection * Childbearing potential unless using an adequate measure of contraception * Pregnancy or lactation. History of hypersensitivity to recombinant proteins * Any clinical finding, including psychiatric and behavioural problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study